Showing results (1921-1930 of 2,044) with videos related to

Sort By:
Pageof 205
Frontiers in Immunology|January 30, 2026
Enhancing anti-tumor immunity through co-blocking PD-L1 and TIGIT by facilitating tumor-directed responses and additional VEGF inhibitionXi Zhu, Xiaopei Cui, Haijia Yu, et al.
European Journal of Cancer (Oxford, England : 1990)|January 23, 2026
SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217)Nai-Jung Chiang, Yung-Yeh Su, I-Wei Ho, et al.
Pharmacological Research|January 7, 2026
Fig-derived exosome-like nanoparticles attenuating bone metastasis of breast cancer through establishing an anti-tumor microenvironmentDan-Dan Wang, Jin Qian, Hui-Zhen Zou, et al.
The New England Journal of Medicine|February 11, 2011
Sunitinib malate for the treatment of pancreatic neuroendocrine tumorsEric Raymond, Laetitia Dahan, Jean-Luc Raoul, et al.
Science Advances|January 25, 2017
ASXL1 interacts with the cohesin complex to maintain chromatid separation and gene expression for normal hematopoiesisZhaomin Li, Peng Zhang, Aimin Yan, et al.
Nature Communications|March 30, 2021
HOXBLINC long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemiaGanqian Zhu, Huacheng Luo, Yang Feng, et al.
Nature Communications|June 6, 2014
Genomic mapping of phosphorothioates reveals partial modification of short consensus sequencesBo Cao, Chao Chen, Michael S DeMott, et al.
Nature Communications|January 2, 2025
Self-assembled materials with an ordered hydrophilic bilayer for high performance inverted Perovskite solar cellsGeping Qu, Letian Zhang, Ying Qiao, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|September 7, 2024
Comprehensive genomic profiling in multiple cancer types: A comparative analysis of the National Biobank Consortium of Taiwan and clinical practice cohortsLing-Jen Hung, Chen-Yang Huang, Kai-Che Tung, et al.
The Lancet. Oncology|December 3, 2014
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trialSung Hoon Noh, Sook Ryun Park, Han-Kwang Yang, et al.
Pageof 205